(Q33409117)

English

Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

medulloblastoma

0 references

0 references

1 reference

based on heuristic

inferred from title

object named as

Adela Cañete

6

0 references

object named as

Pierre Leblond

5

0 references

Darren Hargrave

object named as

Darren Hargrave

18

0 references

1

object named as

Jacques Grill

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

4

object named as

Danuta Perek

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Birgit Geoerger

2

object named as

Birgit Geoerger

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

7

object named as

Isabelle Aerts

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Lyle Gesner

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Luis Madero

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Josep Sanchez de Toledo Codina

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Joris Verlooy

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Edward Estlin

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Laura Cisar

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Aurora Breazna

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Andrew Dorman

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Simon Bailey

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gary Nicolin

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Richard G Grundy

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

European Consortium Innovative Therapies for Children with Cancer (ITCC) and the European Society for Paediatric Oncology (SIOPE) brain tumor group

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

14 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1236-1243

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Medulloblastoma in young children

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Current treatment approaches for infants with malignant central nervous system tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Temozolomide in resistant or relapsed pediatric solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Temozolomide in paediatric high-grade glioma: a key for combination therapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Medulloblastoma: signalling a change in treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Reporting results of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

21 June 2018

Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT097

21 January 2018

Efficacy of temozolomide for recurrent embryonal brain tumors in children

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT097

21 January 2018

Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT097

21 January 2018

O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT097

21 January 2018

Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT097

21 January 2018

Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT097

21 January 2018

Treatment of recurrent central nervous system primitive neuroectodermal tumours in children and adolescents: results of a Children's Cancer and Leukaemia Group study.

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT097

21 January 2018

Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOT097

21 January 2018

Temozolomide in relapsed pediatric brain tumors: 14 cases from a single center

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

31 October 2018

Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

31 October 2018

Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

31 October 2018

Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3748925

31 October 2018

Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23857707

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/NEUONC/NOT097

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33409117&oldid=1764022622"